Astrazeneca Stock Slumps to 1.97% as Daily Trading Volume Hits $290 Million Ranking 355th in Market Activity

Astrazeneca (AZN) closed on Sept. , . The pharmaceutical giant ranked 355th in market activity, reflecting subdued investor interest amid mixed signals from its therapeutic pipeline. Regulatory filings showed no material updates to its key oncology programs, while recent clinical trial timelines remained unchanged despite market speculation about accelerated approvals.

Analysts noted that the stock's underperformance contrasted with broader healthcare sector gains, as investors shifted focus toward biotech innovators with near-term commercialization potential. Short-term technical indicators showed bearish momentum with RSI approaching overbought levels, . Institutional ownership data revealed no significant position adjustments in the past month, suggesting the decline was driven by retail selloff rather than strategic rebalancing.

To run this back-test accurately I need a few clarifications and one practical decision from you: 1. Market universe • Do you want all listed U.S. common stocks, or a subset such as the Russell 3000, S&P 1500, etc.? • If it is a non-U.S. market, please specify the exchange(s). 2. "Top 500 by daily trading volume" • Should the ranking be by share volume or by dollar turnover (volume × price)? • Are corporate actions (splits, symbol changes) to be adjusted for? 3. Trading assumptions • Entry price: next day’s open or same day’s close after the volume is observed? • Exit price: following day’s close (24-hour hold) or the next open? • Any transaction costs or slippage to apply? 4. Practical note on tooling My toolset can pull price/volume data ticker-by-ticker and evaluate strategies, but a daily re-ranking across the entire U.S. equity universe (~4 000 symbols) is computationally heavy in this chat setting. Two common ways to keep the project manageable are: a) Restrict the universe (e.g., the Russell 1000). b) Test the idea on a representative sample or an ETF proxy first.